Showing results (31-40 of 74) with videos related to
Sort By:
Pageof 8
Archives of Physical Medicine and Rehabilitation|February 3, 2007
Changes in flexed posture, musculoskeletal impairments, and physical performance after group exercise in community-dwelling older womenWendy B Katzman, Deborah E Sellmeyer, Anita L Stewart, et al.Diabetes Care|June 29, 2004
Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trialTheresa H M Keegan, Ann V Schwartz, Douglas C Bauer, et al.Diabetes|June 23, 2016
Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 DiabetesDeborah E Sellmeyer, Roberto Civitelli, Lorenz C Hofbauer, et al.JBMR Plus|December 16, 2024
<i>CDC73</i> c.1155-3A>G is a pathogenic variant that causes aberrant splicing, disrupted parafibromin expression, and hyperparathyroidism-jaw tumor syndromeLeor Needleman, Nicolette Chun, Sathvika Sitaraman, et al.Clinical Endocrinology|January 5, 2011
Lean mass and fat mass predict bone mineral density in middle-aged individuals with noninsulin-requiring type 2 diabetes mellitusKendall F Moseley, Devon A Dobrosielski, Kerry J Stewart, et al.Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|June 10, 2011
Lean mass predicts hip geometry in men and women with non-insulin-requiring type 2 diabetes mellitusKendall F Moseley, Devon A Dobrosielski, Kerry J Stewart, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 27, 2015
Sex-specific differences in progressive glucose intolerance and hip geometry: the Baltimore Longitudinal Study of AgingK F Moseley, C W Chia, E M Simonsick, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 3, 2007
Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosisD E Sellmeyer, D M Black, L Palermo, et al.Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|November 25, 2010
Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosisAnne L Schafer, Lisa Palermo, Douglas C Bauer, et al.The Journal of Clinical Endocrinology and Metabolism|July 14, 2012
Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trialAnne L Schafer, Deborah E Sellmeyer, Lisa Palermo, et al.Pageof 8